The Management of People at High Risk of CVD Dr Richard Healicon Mel Varvel NHS Improvement.

Slides:



Advertisements
Similar presentations
Implementing the Stroke Palliative Approach Pathway
Advertisements

Unstable angina and NSTEMI
Implementing NICE guidance
Diabetic Foot Problems
Type 2 diabetes Implementing NICE guidance 2009 NICE clinical guideline 87.
Implementing NICE guidance
Good Medical Practice Evidence to use for Appraisal Good Medical Practice 2006.
CHD REGISTERS ADELE GRAHAM PROJECT MANAGER WEST YORKSHIRE CHD COLLABORATIVE.
PRIMIS Third National Conference Tuesday 1 April 2003 Birmingham HIP for CHD Jane Matthews Practice Nurse Dr. Dai Evans PRIMIS Regional Clinical Adviser.
Summary Prepared by Melvyn Rubenfire, MD
PRIMISFirst National Conference 3rd April 2001 Birmingham.
New Atrial Fibrillation/Flutter Pathway and GRASP Tool
National Service Frameworks Dr Stephen Newell February 2002.
1 Developments and progress Dr Martin Freeman GP Clinical Lead for Dementia Services.
Powys-wide, Primary care audit Rhiannon Davies, Powys tHB Medicines Management Team Prescribing of Antipsychotic Medication in Patients with Dementia.
Task Force on Diabetes and CVD (ESC and EASD) European Heart Journal 2007;28:
L1:Apply the concepts of health and wellness to identify health behaviours and factors influencing choice and change in health using an holistic approach.
Effectiveness of health checks to improve the physical health of patients with severe mental illness: a single blind cluster randomised controlled trial.
QOF Changes 2015/16 Kate Pilton Development Manager.
CHD Prevention and Risk Asssessment: Old concepts new context? Dr Paul D MacIntyre Director of Cardiology, RHH.
The situation The requirements The benefits What’s needed to make it work How to move forward.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Level Health Equally Well Key findings from a literature review informing collaborative efforts to improve the physical health outcomes of people with.
Absolute cardiovascular disease risk Assessment and Early Intervention Dr Michael Tam Lecturer in Primary Care
European Guidelines on CVD prevention ESC Commitee für Practice Guidelines to improve the quality of clinical practice and patient care in Europe Fourth.
Disability and special educational needs: local area responsibilities under the Children and Families Act, 2014 Charlie Henry HMI National lead for disability.
Only You Can Prevent CVD Matthew Johnson, MD. What can we do to prevent CVD?
Establishing Preventive Cardiology Programs Nathan Wong Nathan Wong.
{ A Novel Tool for Cardiovascular Risk Screening in the Ambulatory Setting Guideline-Based CPRS Dialog Adam Simons MD.
Implementing NICE guidance
Introduction Approximately 1 in 3 of adults, have cardiovascular disease vascular/metabolic risk factors such as hypertension, dyslipidemia, and diabetes;
Risk estimation and the prevention of cardiovascular disease SIGN 97.
Management of Stable Angina SIGN 96
Clinical Audit as Evidence for Revalidation Dr David Scott, GMC Associate, Consultant Paediatrician and Clinical Lead for Children’s Services, East Sussex.
Medical Audit.
Needs Assessment: Young People’s Drug and Alcohol Services in Edinburgh City EADP Children, Young People and Families Network Event 7 th March 2012 Joanne.
Respiratory Service Framework Asthma and COPD Care (Nursing) Project Learning and Development Strategy.
Self-reported cognitive and emotional effects and lifestyle changes shortly after preventive cardiovascular consultations in general practice Dea Kehler.
2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults: A Report of the American College.
10 Points to Remember on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in AdultsTreatment of Blood Cholesterol to Reduce.
Tina Huang.  Aimed at people aged 40 – 74  Risk assessment and management programme to prevent or delay the onset of diabetes, heart and kidney disease.
Preventing Surgical Complications Prevent Harm from High Alert Medication- Anticoagulants in Primary Care Insert Date here Presenter:
International Guidelines for Prevention of Atherosclerotic Cardiovascular Disease Prof. Mohamed Sobhy, MD, FACC Professor of Cardiology, Alex. University.
Basic Nursing: Foundations of Skills & Concepts Chapter 9
Cardiac MCN April 2007 Tackling Health Inequalities: Keep Well Programme.
Standard 10: Preventing Falls and Harm from Falls Accrediting Agencies Surveyor Workshop, 13 August 2012.
Using QOF and Service Specifications to meet HI Needs Rachel Foskett-Tharby.
The Management of People at High Risk of CVD Dr Richard Healicon Mel Varvel NHS Improvement Jan Procter-King CVD Nurse & National Trainer.
Corporate slide master With guidelines for corporate presentations Child Measurement Programme Third annual report – 19 May 2015 Welsh Government – the.
PUTTING PREVENTION FIRST Vascular Checks Dr Bill Kirkup Associate NHS Medical Director.
PUTTING PREVENTION FIRST Vascular Checks/ NHS Health Checks.
Objectives of Training To provide you with an overview of MSD Informatics Software. To provide you with sufficient training to be able to use MSD Informatics.
NHS Health Check programme An opportunity to engage 15 million people to live well for longer Louise Cleaver National Programme Support Manager.
ResultsIntroduction Atrial Fibrillation (AF) affects 1.2% 1 of the population and 10% of those over the age of 75 2 It is the commonest arrhythmia in primary.
SECONDARY PREVENTION IN HEART DISEASE CATHY QUICK AUBURN UNIVERSITY/AUBURN MONTGOMERY EBP III.
Excess winter deaths and morbidity and the health risks associated with cold homes Chris Connell Implementation Consultant September 2015.
Brighton and Hove PPMA Preventing Premature Mortality Audit Dr James Simpkin Clinical Facilitator BHPPMA
Early Intervention in Dementia Bernie Coope Consultant Old Age Psychiatrist/Associate Medical Director/Honorary Senior Lecturer, Worcester Association.
Statin use in adults at high risk of cardiovascular disease mortality: cross-sectional analysis of baseline data from the Irish Longitudinal Study on Ageing.
Welcome and Introductions
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Section 9: Continuum of care: Summary and timeline
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
LRC-CPPT and MRFIT Content Points:
Introduction to: 2013 ACC/AHA Guideline on the Treatment of Blood Cholesterol to Reduce Atherosclerotic Cardiovascular Risk in Adults BLUF: -Shift from.
Goals & Guidelines A summary of international guidelines for CHD
Many post-MI patients are not receiving optimal therapy
How to complete a ReSPECT form
Presentation transcript:

The Management of People at High Risk of CVD Dr Richard Healicon Mel Varvel NHS Improvement

Introduction The challenge Meeting the challenge Click here to look inside Your opportunity to contribute

Rationale for CVD Prevention CVD is a major cause of mortality & morbidity & is a significant drain on health care resources Underlying atherosclerosis develops insidiously over many years & is usually advanced by the time symptoms occur Death from CVD often occurs suddenly & before medical care is available so that therapeutic interventions are either inapplicable or palliative Prevalence of CVD relates strongly to lifestyles & modifiable physiological & biochemical factors Risk factor modifications have been shown to reduce CVD mortality & morbidity, particularly in high risk subjects Eur Heart J (2007) 28 (19):

Management of high risk people Continued confusion about whether people at high risk are eligible/stay in the programme People on statins are excluded because they will have already had a risk assessment and should be managed according to NICE guidelines. People who are found to be at or above 20% risk should exit the programme irrespective of whether they have signs of disease People at or above 20% risk without disease should be placed on a high risk register and managed accordingly Work with NHS I to improve use of high risk registers and management of high risk people about to start

Policy Context: NHS Health Check

Policy Context: NSF for CHD Standard four: General practitioners and primary health care teams should identify all people at significant risk of cardiovascular disease but who have not yet developed symptoms and offer them appropriate advice and treatment to reduce their risks. Milestone 2: Every practice should have: a systematically developed and maintained practice-based register of people with clinical evidence of CHD, occlusive vascular disease AND of people whose risk of CHD events is > 30% over ten years in place and actively used to provide structured care to those at high risk of CHD.

Policy Context: NSF for CHD Milestone 3: Every practice should have: a protocol describing the systematic assessment, treatment and follow- up of people at high risk of CHD, including those without evidence of existing arterial disease but whose risk of CHD events is > 30% over ten years, agreed locally and being used to provide structured care to people with CHD. Milestone 4: Every practice should have: clinical audit data no more than 12 months old available that describes all the items listed in paragraph 13 on page 4 [see CHD NSF Chapter Two]. The NSF goal: Every practice should: offer advice about each of the specified effective interventions to all of those in whom they are indicated, demonstrated by clinical audit data no more than 12 months old.

Existing Guidelines: JBS2 We recommend that CVD prevention in clinical practice should focus equally on (i) people with established atherosclerotic CVD, (ii) people with diabetes, and (iii) apparently healthy individuals at high risk (CVD risk of > 20% over 10 years) of developing symptomatic atherosclerotic disease. This is because they are all people at high risk of CVD. These three groups all require professional lifestyle and multifactorial risk factor management to defined lifestyle and risk factor targets. HEART Vol. 91, Supplement V, Dec 2005

Published Guidance: NICE For the primary prevention of CVD in primary care, a systematic strategy should be used to identify people aged 40–74 who are likely to be at high risk. People should be prioritised on the basis of an estimate of their CVD risk before a full formal risk assessment. Their CVD risk should be estimated using CVD risk factors already recorded in primary care electronic medical records. Risk equations should be used to assess CVD risk. People should be offered information about their absolute risk of CVD and about the absolute benefits and harms of an intervention over a 10-year period.

Published Guidance: QOF Secondary prevention of coronary heart disease (CHD1-CHD14): –Records (Register) –Ongoing Management (Review) Cardiovascular disease: Primary prevention (PP1-PP2) –Initial diagnosis (Risk Assessment) –Ongoing Management (Lifestyle advice)

The First Step “A Journey of a thousand miles must begin with a single step” Lao Tzu, Chinese Philosopher

Meeting the Challenge Short, practical ‘how to’ guide Outlines existing guidance Includes examples of good practice Points to other sources of advice and information The Management of People at High Risk of CVD

Overview of Contents Introduction –About this guide –How to use it Background –Rationale –Policy context Establishing & Maintaining a Register –Defining & identifying those at ‘high risk’ –Creating & validating a register –Risk assessment Managing People at High Risk of CVD –Communication of risk –Management of risk factors –Follow-up: Annual review –Training & competencies –Reaching the ‘hard to reach’ –Levers/Incentives –Cost, capacity –Case studies

Purpose of Today Present the story so far Identify & share good practice Provide an opportunity to discuss issues & challenges (& reach a consensus on some) Contribute to the development of the guide –10-15 mins to debate and discuss key questions under 3 headings –Record ‘consensus’ and good practice examples (with contact details) on post-it notes and stick on relevant flip chart –We will summarise feedback at end

High CVD risk Definition-risk algorithm Creating a register –Do we have adequate codes –Exclusion codes Validating the register Examples

Management of those at high CVD risk Annual review-suggested in the NHS Health Checks document What should it include? –Recalculate risk? –Cholesterol? –Role of lifestyle interventions Examples

Management of those at high CVD risk Pharmacological –Statins –Review –monitoring Lifestyle interventions –Definition of adequate trial –‘informed dissent’ Examples